A Look at WCLC 2026: Pivotal Trials and Emerging Directions
Triparna Sen, PhD
Making the Most of WCLC 2026: A Guide for Early-Career Professionals
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Steve Jackson, PharmD
Apar Kishor Ganti, MD
Thomas Marron, MD, PhD
Axatilimab’s Impact on cGVHD and Associated BOS
Charles Turck, PharmD, BCPS, BCCCP
Amandeep Salhotra, MD
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Multiple dates available
Patient-Centered Care in ALK+ Non-Small Cell Lung Cancer
Jorge Nieva, MD
Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Beyond ALK Inhibition: Addressing Unmet Needs in Non-Small Cell Lung Cancer
Urs Weber, MD
Building on Progress in ALK+ Non-Small Cell Lung Cancer Treatment
Side Effect Management in ALK+ Non-Small Cell Lung Cancer Care
Comprehensive Molecular Testing in ALK+ Non-Small Cell Lung Cancer
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Nicolas Girard, MD
Louise Lim, MD
Jacob Sands, MD
Stephanie McDonald, MSN, FNP-BC, AOCNP
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Lyudmila A. Bazhenova, MD
Assessing and Interpreting pCR in Perioperative NSCLC
Alexander Spira, MD, PhD, FACP
Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS
Lowell B. Anthony, MD, FACP
Managing Immunotherapy Toxicities in Lung Cancer Patients
Aliyah Pabani, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.